Showing results (31-40 of 225) with videos related to
Sort By:
Pageof 23
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|March 7, 2021
[Evaluation of the prognostic value of MIPSS70-plus in Chinese patients with primary myelofibrosis]X Yan, B Li, T J Qin, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|November 2, 2016
[Efficacy and safety of JAK inhibitor ruxolitinib in Chinese patients with myelofibrosis: results of a 1-year follow-up of A2202]J Jin, X Du, D B Zhou, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 7, 2025
[Next-generation sequencing-based minimal residual disease detection reveals clonal evolution in pediatric acute B-lymphoblastic leukemia: a case report and literature review]J Chang, Y J Jia, H X Wang, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|December 20, 2019
[Analysis of clinical characteristics, treatment response rate and survival of 77 myelodysplastic syndrome patients with del (5q) syndrome]D Liu, Z F Xu, T J Qin, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 11, 2024
[Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world]Q Y Gao, B Li, S Q Qu, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|June 25, 2023
[Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase]X Yan, T J Qin, B Li, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|February 2, 2019
[Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study]Z F Xu, T J Qin, H L Zhang, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|February 9, 2026
[External validation and incremental value assessment of the RR6 prognostic model in Chinese myelofibrosis patients treated with ruxolitinib: focusing on overall survival]N N Liu, B Li, T J Qin, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 17, 2017
[The efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts treated with decitabine alone or CAG/HAG regimen]Z F Xu, T J Qin, H L Zhang, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 28, 2020
[Molecular features and prognostic value of RAS mutations in patients with myelodysplastic syndromes]H J Huang, B Li, T J Qin, et al.Pageof 23